انطلاقاً من الدور التوعوي الذي تقوم به الهيئة العامة للغذاء والدواء فقد قام قطاع الغذاء بتقديم مطوية توعوية على بوابة الهيئة الالكترونية على الانترنت، بعنوان "مواد التعبئة والتغليف" حيث يؤثر الاستخدام غير السليم للمواد البلاستيكية التي تلامس الأغذية على صحة المستهلك بشكل سلبي، ويعتبر من الضروري الالتزام باتباع احتياطات السلامة عند استخدام العبوات والمغلفات البلاستيكية لتعبئة وتغليف الأغذية.

Taking vitamin E supplements does not reduce a woman's risk of rheumatoid arthritis (RA), an analysis of data from the Women's Health Study indicates.

"Despite plausible biologic mechanisms," the present randomized, controlled trial does not show that long-term use of vitamin E supplements significantly decreases the risk of developing RA, Dr. Elizabeth W. Karlson and co-researchers conclude.

Background: Trials evaluating angiotensin-receptor blockers in heart failure (HF) have shown inconsistent results.

Objective: To evaluate the effect of angiotensin II (AII) receptor blockers in HF patients on total mortality and HF hospitalisations.

The European Committee for Medicinal Products for Human Use (CHMP) has

reviewed the risk of nephrogenic systemic fibrosis (NSF) with gadolinium containing

contrast agents.

On the basis of current evidence, the risk classification is as follows:

High risk—Omniscan (gadodiamide), OptiMARK (gadoversetamide),Magnevist (gadopentetic acid)

The U.S. Food and Drug Administration today approved Lyrica (pregabalin), the first drug to treat fibromyalgia, a disorder characterized by pain, fatigue and sleep problems.

Lyrica reduces pain and improves daily functions for some patients with fibromyalgia.

Background

Use of angiotensin-converting enzyme (ACE) inhibitors during the second and third trimesters of pregnancy is contraindicated because of their association with an increased risk of fetopathy. In contrast, first-trimester use of ACE inhibitors has not been linked to adverse fetal outcomes. We conducted a study to assess the association between exposure to ACE inhibitors during the first trimester of pregnancy only and the risk of congenital malformations.

Methods

Sweden. The Swedish Adverse Drug Reactions Database contains 86 reports of suspected adverse reactions associated with glucosamine products from 2001 until February 2006, according to the Swedish Medical Products Agency. The Agency says that the majority of these cases were reported after 2002, when the first glucosamine product, Artrox, was approved as a drug. According to the Agency, there are now just over 10 glucosamine products approved in Sweden, including Artrox, Glucosine, Glukosamin Copyfarm and Glukosamin Pharma.